Orphan Drug “Improvements” May Be Undercut By New Market Share Fees
Executive Summary
The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.